drugset / Trial / NCT00687934

Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors

NCT00687934

Phase 1 Completed 53 enrolled Synta Pharmaceuticals Corp.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

An open-label dose escalation study of patients with solid tumors treated with STA-9090 (ganetespib)

Timeline

Start
2007-10
Primary completion
2011-06
Completion
2011-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganetespib Small molecule 7 mg/m2 Intravenous
Subject Ganetespib Small molecule 150 mg/m2 Intravenous
Subject Ganetespib Small molecule 200 mg/m2 Intravenous
Subject Ganetespib Small molecule 216 mg/m2 Intravenous
Subject Ganetespib Small molecule 259 mg/m2 Intravenous

Indications